Form D · Other
WPD Pharmaceuticals Inc.
Vancouver, A1 · CIK 0001798073
Offering snapshot reported Feb 11, 2020 · SEC filing
- Reported sold
- Yet to sell Offering amount: $890K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 11, 2020 | Initial | Yet to sell | No comparison | 3 | SEC filing |
| Jan 3, 2020 | Initial | $16,852,353 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-360240
CDN$1,161,000 based on Bank of Canada Exchange rate of $0.7664 on January 13, 2020. Represents stock options to purchase 1,350,000 common shares at an exercise price of CDN$0.86 per share.
Source: Form D, filed Feb 11, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Cherry | Executive |
| Liam Lake Corcoran | Director, Executive |
| Walter Klemp | Director |
| Yari Nieken | Director, Executive |
| Peter Novak | Director |
| Mariusz Olejniczak | Executive |
| Teresa Rzepczyk | Director |
Issuer details
Industry: Other (See others in industry)
Address:
Suite 1080, 789 West Pender Street
Vancouver, A1, V6C 1H2
Vancouver, A1, V6C 1H2